This site is intended only for healthcare professionals residing in Singapore
Pfizer has a long-standing commitment to tackling antimicrobial resistance (AMR), as well as a willingness to collaborate with antimicrobial stewardship committees and other stakeholders. Our current initiatives focus on an extensive range of programmes that go beyond the sale of our medicines, including public awareness and educational programmes, education of healthcare professionals, responsible commercial and manufacturing activities and investment in surveillance programmes.
Explore clinical evidence and resources to help healthcare professionals in the management of patients with invasive fungal infections. Think Fungus, Save Lives.
Explore clinical evidence and resources to help healthcare professionals in the management of patients at high risk of multidrug resistant Gram-negative infections.
Explore clinical evidence and resources to help healthcare professionals in the management of CAP and cSSTI patients of all ages including those at risk of initial treatment failure.
Come aboard the Pfizer Bug Bus to learn about AMR and steps each of us can take to help #StopSuperbug
Our habits need to change before microbes change theirs. Pfizer’s antimicrobial resistance hub aims to be the most comprehensive and current of its kind. We’re giving you unrestricted access.
Join us in the fight against antimicrobial resistance.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
Copyright © 2024 Pfizer Limited. All rights reserved.